Effect of enhanced external counterpulsation therapy on myeloperoxidase in lowering cardiovascular events of patients with chronic heart failure

  • Starry H. Rampengan Departement of Cardiology and Vascular Medicine, Faculty of Medicine, University Sam Ratulangi, Manado, Indonesia
  • Budhi Setianto Departement of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Jimmy Posangi Departement of Pharmacology, Faculty of Medicine, University Sam Ratulangi, Manado, Indonesia
  • Suzanna Immanuel Departement of Clinical Pathology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Judo Prihartono Departement of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Minarma Siagian Departement of Physiology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Harmani Kalim Departement of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Sirowanto Inneke Departement of Obstetric and Gynecology, Awal Bros Hospital, Tangerang, Indonesia
  • Murdani Abdullah Departement of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Sarwono Waspadji Departement of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Abstract viewed: 1088 times
PDF downloaded: 349 times

Abstract

Background: Chronic heart failure (CHF) is a slowly progressive disease with high morbidity and mortality; therefore, the management using pharmacological treatments frequently fails to improve outcome. Enhanced external counterpulsation (EECP), a non-invasive treatment, may serve as alternative treatment for heart failure. This study was aimed to evaluate the influence of EECP on myeloperoxidase (MPO) as inflammatory marker as well as cardiac events outcome.

Methods: This was an open randomized controlled clinical trial on 66 CHF patients visiting several cardiovascular clinics in Manado between January-December 2012. The subjects were randomly divided into two groups, i.e. the group who receive EECP therapy and those who did not receive EECP therapy with 33 patients in each group. Myeloperoxidase (MPO) as inflammatory marker was examined at baseline and after 6 months of observation. Cardiovascular events were observed as well after 6 months of observation. Unpaired t-test was use to analyze the difference of MPO between the two groups, and chi-square followed by calculation of relative risk were used for estimation of cardiovascular event outcomes.

Results: MPO measurement at baseline and after 6 months in EECP group were 643.16 ± 239.40 pM and 422.31 ± 156.26 pM, respectively (p < 0.001). Whereas in non EECP group, the MPO values were 584.69 ± 281.40 pM and 517.64 ± 189.68 pM, repectively (p = 0.792). MPO reduction was observed in all patients of EECP group and in 13 patients (48%) of non-EECP group (p < 0.001). Cardiovascular events were observed in 7 (21.21%) and 15 (45.45%) of patients in EECP and non-EECP groups, respectively (p = 0.037).

Conclusion: EECP therapy significantly decreased the level of MPO as inflammatory marker and this decrease was correlated with the reduction of cardiovascular events in CHF patients. (Med J Indones. 2013;22:152-60. doi: 10.13181/mji.v22i3.584)

Keywords: CHF, cardiovascular events, EECP, myeloperoxidase

Published
2013-08-22
How to Cite
1.
Rampengan SH, Setianto B, Posangi J, Immanuel S, Prihartono J, Siagian M, Kalim H, Inneke S, Abdullah M, Waspadji S. Effect of enhanced external counterpulsation therapy on myeloperoxidase in lowering cardiovascular events of patients with chronic heart failure. Med J Indones [Internet]. 2013Aug.22 [cited 2019Nov.22];22(3):152-60. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/584
Section
Clinical Research